• Je něco špatně v tomto záznamu ?

Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile

T. Kropáčková, L. Vernerová, H. Štorkánová, V. Horváthová, M. Vokurková, M. Klein, S. Oreská, M. Špiritović, B. Heřmánková, K. Kubínová, LA. Cerezo, O. Kryštůfková, H. Mann, J. Ukropec, B. Ukropcová, J. Zámečník, M. Tomčík, J. Vencovský, L. Šenolt

. 2021 ; 39 (5) : 1021-1032. [pub] 20201029

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024996

Grantová podpora
NV16-33746A MZ0 CEP - Centrální evidence projektů
NV16-33746A MZ0 CEP - Centrální evidence projektů

OBJECTIVES: The aim of this cross-sectional study was to explore the circulating and skeletal muscle expression of clusterin (CLU) in inflammatory myopathies (IIM) and its potential implication in pathogenetic mechanisms of the disease. METHODS: A total of 85 IIM patients and 86 healthy controls (HC) were recruited. In addition, 20 IIM patients and 21 HC underwent a muscle biopsy. Circulating CLU was measured by ELISA. Serum cytokine profile of patients and HC was assessed by Cytokine 27-plex Assay. Immunohistochemical localisation of CLU was assessed in 10 IIM and 4 control muscle tissue specimens. The expression of CLU and myositis related cytokines in muscle was determined by qPCR. RESULTS: Serum levels of CLU were significantly increased in IIM patients compared to controls (86.2 (71.6-99.0) vs. 59.6 (52.6-68.4) μg/mL, p<0.0001) and positively correlated with myositis disease activity assessment (MYOACT) (r=0.337, p=0.008), myositis intention-to-treat activity index (MITAX) (r=0.357, p=0.004) and global disease assessment evaluated by physician (r=0.309, p=0.015). Moreover, serum CLU correlated with cytokines and chemokines involved in IIM and their combined effect on disease activity was revealed by multivariate redundancy analysis. In muscle tissue, CLU mRNA was increased in IIM patients compared to controls (p=0.032) and CLU accumulated in the cytoplasm of regenerating myofibres. CONCLUSIONS: We suggest that the up-regulation of clusterin in circulation and skeletal muscle of IIM patients may be an inflammation and atrophy induced response of the organism intended to limit the environment, favouring further muscle damage.

000      
00000naa a2200000 a 4500
001      
bmc21024996
003      
CZ-PrNML
005      
20211026134222.0
007      
ta
008      
211013s2021 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)33124569
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Kropáčková, Tereza $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile / $c T. Kropáčková, L. Vernerová, H. Štorkánová, V. Horváthová, M. Vokurková, M. Klein, S. Oreská, M. Špiritović, B. Heřmánková, K. Kubínová, LA. Cerezo, O. Kryštůfková, H. Mann, J. Ukropec, B. Ukropcová, J. Zámečník, M. Tomčík, J. Vencovský, L. Šenolt
520    9_
$a OBJECTIVES: The aim of this cross-sectional study was to explore the circulating and skeletal muscle expression of clusterin (CLU) in inflammatory myopathies (IIM) and its potential implication in pathogenetic mechanisms of the disease. METHODS: A total of 85 IIM patients and 86 healthy controls (HC) were recruited. In addition, 20 IIM patients and 21 HC underwent a muscle biopsy. Circulating CLU was measured by ELISA. Serum cytokine profile of patients and HC was assessed by Cytokine 27-plex Assay. Immunohistochemical localisation of CLU was assessed in 10 IIM and 4 control muscle tissue specimens. The expression of CLU and myositis related cytokines in muscle was determined by qPCR. RESULTS: Serum levels of CLU were significantly increased in IIM patients compared to controls (86.2 (71.6-99.0) vs. 59.6 (52.6-68.4) μg/mL, p<0.0001) and positively correlated with myositis disease activity assessment (MYOACT) (r=0.337, p=0.008), myositis intention-to-treat activity index (MITAX) (r=0.357, p=0.004) and global disease assessment evaluated by physician (r=0.309, p=0.015). Moreover, serum CLU correlated with cytokines and chemokines involved in IIM and their combined effect on disease activity was revealed by multivariate redundancy analysis. In muscle tissue, CLU mRNA was increased in IIM patients compared to controls (p=0.032) and CLU accumulated in the cytoplasm of regenerating myofibres. CONCLUSIONS: We suggest that the up-regulation of clusterin in circulation and skeletal muscle of IIM patients may be an inflammation and atrophy induced response of the organism intended to limit the environment, favouring further muscle damage.
650    12
$a klusterin $x genetika $7 D051152
650    _2
$a průřezové studie $7 D003430
650    _2
$a cytokiny $7 D016207
650    _2
$a lidé $7 D006801
650    _2
$a kosterní svaly $7 D018482
650    12
$a myozitida $7 D009220
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vernerová, Lucia $u Institute of Rheumatology, Prague, Czech Republic. vernerova@revma.cz
700    1_
$a Štorkánová, Hana $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Horváthová, Veronika $u Institute of Rheumatology, Prague, and Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Vokurková, Martina $u Institute of Rheumatology, Prague, Czech Republic
700    1_
$a Klein, Martin $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Oreská, Sabína $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Špiritović, Maja $u Institute of Rheumatology, Prague, and Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic
700    1_
$a Heřmánková, Barbora $u Institute of Rheumatology, Prague, Czech Republic 4 Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic
700    1_
$a Kubínová, Kateřina $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Cerezo, Lucie Andrés $u Institute of Rheumatology, Prague, Czech Republic
700    1_
$a Kryštůfková, Olga $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mann, Heřman $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Ukropec, Jozef $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
700    1_
$a Ukropcová, Barbara $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, and Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Zámečník, Josef $u Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic
700    1_
$a Tomčík, Michal $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Vencovský, Jiří $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Šenolt, Ladislav $u Institute of Rheumatology, Prague, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00001116 $t Clinical and experimental rheumatology $x 0392-856X $g Roč. 39, č. 5 (2021), s. 1021-1032
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33124569 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134228 $b ABA008
999    __
$a ok $b bmc $g 1714165 $s 1145503
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 39 $c 5 $d 1021-1032 $e 20201029 $i 0392-856X $m Clinical and Experimental Rheumatology $n Clin Exp Rheumatol $x MED00001116
GRA    __
$a NV16-33574A $a NV16-33746A $p MZ0 $p MZ0
GRA    __
$a NV16-33574A $a NV16-33746A $p MZ0 $p MZ0
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace